Subsequent trials assessing the efficacy of second-line trastuzumab combinations, lapatinib, and trastuzumab emtansine in HER2-positive gastric cancer patients who had progressed on trastuzumab did not yield positive results [169]. The gene discussed is ERBB2; the disease is gastric cancer.